The company’s growth trajectory remains tied to the rapid adoption of its integrated CRDMO services, with 15 of the world's top 20 pharmaceutical firms now among its partners. Gross profit reached RMB 1.37 billion, reflecting a 40.6% increase period-over-period, while margins improved by 0.9 percentage points to 37%. This operational efficiency gain stems from higher facility utilization and the successful scaling of newer production lines.
In section Releases
WuXi XDC reports 37% revenue growth as bioconjugate demand surges
WuXi XDC Cayman Inc. posted a strong first half for 2026, with total revenue climbing to RMB 3.7 billion. The global bioconjugate leader saw its service backlog swell to over USD 2 billion, fueled by an expanding customer base and the successful integration of newly acquired manufacturing capabilities.
Management credits the "Enable, Follow and Win the Molecule" strategy for the surge in project volume, which now totals 328 integrated CMC projects. The acquisition of BioDlink in March 2026 and the recent GMP release of the Singapore facility have provided the necessary infrastructure to support this pipeline, which includes 21 process performance qualification projects and two commercial-stage programs. CEO Jimmy Li noted that the firm is well-positioned to capitalize on the diversifying bioconjugate market, which now encompasses complex modalities like antibody-oligonucleotide and antibody-peptide conjugates.
Comments (0)
No comments yet. Be the first!